Axsome Therapeutics enters the week of August earnings season with a rare alignment of bullish analyst momentum and quietly rising short interest — a combination that sets up an interesting tension heading into its August 3 Q1 results.
The Street has turned more constructive in recent weeks. RBC Capital lifted its target to $304 from $302 on July 7, reinforcing an Outperform rating, while TD Cowen pushed its target sharply higher to $300 from $275 in mid-June. The broader analyst cluster is pointing up: the consensus mean target now sits at $276.56, roughly 11% above the current price of $249.76, with the bulk of recent moves being upgrades or target increases rather than downgrades. Morgan Stanley remains the holdout with an Equal-Weight and a $242 target — below the current price — but even they lifted from $217 after the last earnings print. The bull case rests on accelerating prescription adoption for Axsome's approved CNS drugs and a forward EPS estimate that has been revised sharply higher, ranking in the 97th percentile on both 30- and 90-day EPS momentum. Bears point to the early-stage pipeline risk, particularly around the smoking cessation trial, and to a valuation that remains stretched — a P/E multiple of 135x and price-to-book above 92x, even as those multiples have compressed meaningfully over the past month.
Short interest tells a nuanced story. At 6.5% of the free float, the short position is not extreme but is also not trivial. More interesting is the trajectory: short interest has risen roughly 18% over the past month, jumping from around 2.76 million shares in early June to 3.26 million. That monthly buildup stands out even as the week-on-week change is nearly flat, suggesting the bulk of the new positioning came earlier in June rather than in the most recent sessions. The borrow market, however, offers no support to bears looking for a squeeze: availability is exceptionally loose at the maximum reading, with over 35 million shares available to lend against just 3.3 million borrowed — a ratio so wide it confirms there is no meaningful constraint on new short supply. Cost to borrow has fallen 28% on the week to just 0.41%, near its lowest level in the 30-day window. Borrow conditions are simply not tight enough to create squeeze pressure.
Options positioning has eased meaningfully from where it was. The put/call ratio has dropped to 0.874, now running below its 20-day average of 0.91 — a mild shift toward call-side activity relative to the more defensive posture that prevailed through May and early June, when the PCR was consistently above 1.0. The z-score of –0.86 confirms this is not a statistically extreme reading in either direction. Taken together, the positioning setup looks more balanced than charged: shorts have rebuilt their position over the past month but the borrow market is wide open, and options traders have rotated away from the defensive hedges they were buying six weeks ago.
Institutional ownership adds one wrinkle worth noting. Antecip Capital remains the dominant holder at 14.3% of shares and reported no change as of mid-April. BlackRock added 253,614 shares through June 30, and Fidelity (FMR) added 385,311 — both meaningful increments from two of the largest passive and active managers. On the insider side, CEO Herriot Tabuteau sold just under 50,000 shares on July 1 at $240.25, a transaction worth roughly $11.9 million. A similar-sized sale came on June 9, with the CFO also selling 33,000 shares that day for nearly $8 million. The cluster of executive sales at these levels is worth tracking, though the net 90-day insider figure is positive at roughly 164,000 shares net — likely reflecting prior award grants.
The next hard test is earnings on August 3. The stock gained 8% on the day following its most recent print in May, then extended another 4.8% over the subsequent week. The one before that delivered a 1.6% day-one move with a 10.2% five-day follow-through. Whether the pattern of post-earnings strength continues — against a backdrop of rebuilding short interest, loose borrow conditions, and an options market that has recently shifted toward calls — is the question that will define the next leg.
See the live data behind this article on ORTEX.
Open AXSM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
